Tandospirone Citrate

【API structure】

【Project Description】

Tandospirone Citrate Capsules were first successfully developed by Sumitomo Pharmaceuticals of Japan. Sichuan Creed Pharmaceutical Co., Ltd. began research and development in 2001, obtained clinical research approval in November 2003, and obtained production approval in November 2005 and was launched domestically. . Its indications: (1) Anxiety states caused by various neuroses, such as generalized anxiety disorder; (2) Anxiety states associated with physical diseases such as essential hypertension and peptic ulcer.

Tandospirol citrate is a new type of 5-HT1A receptor partial agonist. It is a third-generation new anti-anxiety drug. It mainly acts on the limbic system of the brain and is highly selective for 5-HT1A receptors. By inhibiting 5-HT1A receptors, it is -HT nerve impulses are increased, producing anti-anxiety and anti-depressant effects. It has no dependence, sedation, muscle relaxation, motor inhibition and other side effects, and has good clinical pharmacological properties.
Tandospirol citrate has a synergistic effect with antipsychotic drugs (such as combined with SSRIs), which can not only avoid the common problem of delayed onset of action; it can also enhance the efficacy of antipsychotic drugs and reduce the dosage of psychotropic drugs, thus reducing occurrence of adverse reactions. In the field of hypertension, Lukang can enhance the antihypertensive effect of conventional hypertension drugs, reduce blood pressure fluctuations, and reduce the occurrence of cardiovascular events, especially for patients with M-type hypertension; Lukang can also improve functional gastrointestinal diseases. The patient's mental and physical symptoms. It is widely used in psychiatry, neurology, cardiology, gastroenterology, etc. Our company’s tablets are about to submit application materials